Handa Sanjeev, Singh Gurjeet, Arora Amanjot Kaur, Khandelwal Niranjan, Gupta Vivek
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Radiodiagnosis, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Dermatol Venereol Leprol. 2018;84(2):174-178. doi: 10.4103/0378-6323.204202.
The use of glucocorticoids in various forms of administration is complicated by their systemic side effects. Although intravenous pulse therapy is considered to have lesser systemic side effects, there are few studies in literature comparing the effects of intravenous pulse glucocorticoids versus oral daily glucocorticoids on bone mineral density.
To compare the effects of intravenous pulse glucocorticoids and oral daily glucocorticoids on bone mineral density with the aim of finding any site-specific osteopenic side effect.
The study was conducted by the department of dermatology of Postgraduate Institute of Medical Education and Research, Chandigarh, India. The study comprised of two groups of patients. Group A consisted of 28 patients with pemphigus vulgaris who received intravenous pulses of dexamethasone at 4 weekly intervals. Group B consisted of 21 patients with airborne contact dermatitis who received oral daily prednisolone therapy. All the patients had a dual X-ray absorptiometry scan at baseline, and at 3 and 6 months of follow-up. The results were analyzed as changes in bone mineral density.
There was loss of bone mineral density at lumbar spine and the head of radius in both the groups. At the lumbar spine, Group B showed more reduction in bone mineral density at 3 months whereas in Group A it was more at the head of radius. In patients on oral steroids, the lumbar spine was significantly more affected than the head of radius at both 3 and 6 months of follow-up. However, in patients on intravenous pulse steroids, both the sites were equally affected at 3 and 6 months.
In our study, we used different glucocorticoids in the two groups: prednisolone in the oral daily group and dexamethasone in the intravenous pulse steroids group. A similar reduction in bone mineral density in both the groups may have been due to a longer half-life or more bone-directed side effects of dexamethasone as compared to prednisolone.
Dermatologists need to be aware of the detrimental effects of high-dose intravenous pulsed glucocorticoids on bone mineral density and assessment of this parameter should be done before the initiation of therapy and also at regular intervals thereafter. During follow up, either the lumbar spine or the head of radius can be used to assess the osteopenic effect of intravenous pulse steroids, whereas the lumbar spine is a better site for this evaluation in patients on oral steroids.
糖皮质激素的各种给药方式会因全身副作用而变得复杂。尽管静脉脉冲疗法被认为全身副作用较小,但文献中很少有研究比较静脉脉冲糖皮质激素与口服每日糖皮质激素对骨密度的影响。
比较静脉脉冲糖皮质激素和口服每日糖皮质激素对骨密度的影响,以发现任何特定部位的骨质减少副作用。
该研究由印度昌迪加尔医学教育与研究研究生院皮肤科进行。该研究包括两组患者。A组由28例寻常型天疱疮患者组成,他们每隔4周接受一次地塞米松静脉脉冲治疗。B组由21例空气传播性接触性皮炎患者组成,他们接受口服每日泼尼松龙治疗。所有患者在基线时以及随访3个月和6个月时均进行了双能X线吸收测定扫描。结果以骨密度变化进行分析。
两组患者的腰椎和桡骨头部均出现骨密度降低。在腰椎,B组在3个月时骨密度降低更多,而在A组,桡骨头部降低更多。在口服类固醇的患者中,在随访3个月和6个月时,腰椎比桡骨头部受影响更显著。然而,在接受静脉脉冲类固醇治疗的患者中,在3个月和6个月时,两个部位受影响程度相同。
在我们的研究中,两组使用了不同的糖皮质激素:口服每日组使用泼尼松龙,静脉脉冲类固醇组使用地塞米松。两组骨密度的类似降低可能是由于地塞米松与泼尼松龙相比半衰期更长或骨靶向副作用更多。
皮肤科医生需要意识到高剂量静脉脉冲糖皮质激素对骨密度的有害影响,并且应在治疗开始前以及此后定期对该参数进行评估。在随访期间,腰椎或桡骨头部均可用于评估静脉脉冲类固醇的骨质减少作用,而对于口服类固醇的患者,腰椎是进行此评估的更好部位。